BioNxt Solutions Inc. (FRA:BXT)
0.5020
0.00 (0.00%)
Last updated: Oct 23, 2025, 11:21 AM CET
BioNxt Solutions Revenue
BioNxt Solutions had revenue of 21.66K CAD in the twelve months ending June 30, 2025, down -29.29% year-over-year. In the year 2024, BioNxt Solutions had annual revenue of 26.99K, down -92.75%.
Revenue (ttm)
21.66K CAD
Revenue Growth
-29.29%
P/S Ratio
4,687.78
Revenue / Employee
n/a
Employees
n/a
Market Cap
63.41M EUR
Revenue Chart
* This company reports financials in CAD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 26.99K | -345.26K | -92.75% |
| Dec 31, 2023 | 372.25K | 74.81K | 25.15% |
| Dec 31, 2022 | 297.44K | 10.94K | 3.82% |
| Dec 31, 2021 | 286.50K | -59.16K | -17.11% |
| Dec 31, 2020 | 345.65K | 137.54K | 66.08% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Mercedes-Benz Group AG | 139.36B |
| Bayerische Motoren Werke Aktiengesellschaft | 136.51B |
| Deutsche Telekom AG | 120.55B |
| Allianz SE | 109.02B |
| Siemens Aktiengesellschaft | 78.30B |
| Münchener Rückversicherungs-Gesellschaft Aktiengesellschaft in München | 62.33B |
| Siemens Energy AG | 38.39B |
| SAP SE | 35.89B |
BioNxt Solutions News
- 2 days ago - BioNxt Launches 15-day Sublingual Cladribine Dosing Optimization Study in Preparation for Human Bioequivalence Study - Wallstreet:Online
- 14 days ago - BioNxt Solutions Provides Update To Annual General Meeting Matters Due To Canadian Postal Strike And IR Activities - Wallstreet:Online
- 14 days ago - BioNxt Completes "Fast-Track" US Track One Patent Filing for Sublingual Delivery of Cladribine for the Treatment of Multiple Sclerosis - Wallstreet:Online
- 21 days ago - BioNxt Reports Update on Targeted Chemotherapy Drug Delivery Platform - Wallstreet:Online
- 24 days ago - BioNxt Reports Sublingual Cladribine Multiple Sclerosis Drug Milestones Including Large-Animal Study for Validation and Dosing Optimization - Wallstreet:Online
- 4 weeks ago - BioNxt Solutions Announces Closing of Shares for Debt Settlement - Wallstreet:Online
- 4 weeks ago - Terry Lynch Continues as Capital Markets Advisor and BioNxt Retains Investor Relations Professionals - Wallstreet:Online
- 5 weeks ago - BioNxt Advances Semaglutide Oral Dissolvable Film (ODF) Program with Successful Proof-of-Concept and Prototype Development - Wallstreet:Online